- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00516659
ETEC Logistics Trial (TREK) (Trek)
A Phase II, Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Epidemiology of Natural Infection With Enterotoxigenic Escherichia Coli Occurring After Transcutaneous Immunization in a Field Setting
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The primary objectives of the study are to evaluate the incidence of ETEC illness in a field setting and to compare the safety of LT delivered by TCI with placebo. The secondary objectives include, but are not limited to:
evaluate the stool frequency per episode of ETEC illness in placebo recipients, to evaluate the immunogenicity of LT delivered by TCI, to evaluate the incidence of IBS following travel to areas of ETEC endemnicity, and to evaluate the incidence of VPO in placebo and LT patch recipients.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
California
-
Long Beach, California, Förenta staterna, 90806
- West Coast Clinical Trials
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60610
- Radiant Research
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21205
- Johns Hopkins University, Bloomberg School of Public Health
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna, 55430
- Twin Cities Clinical Research
-
-
New Jersey
-
Hackensack, New Jersey, Förenta staterna, 07601
- Advanced Biomedical Research
-
-
New York
-
Ithica, New York, Förenta staterna, 14850
- Asthma Allergy & Associates
-
-
Ohio
-
Columbus, Ohio, Förenta staterna, 43212
- Radiant Research
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75235
- Radiant Research
-
Houston, Texas, Förenta staterna, 77024
- Breco Research
-
Houston, Texas, Förenta staterna, 77030
- Center for Infectious Diseases, The University of Texas Health Science Center at Houston
-
San Antonio, Texas, Förenta staterna, 78229
- Radiant Research
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84124
- Jean Brown Research
-
-
Washington
-
Tacoma, Washington, Förenta staterna, 98418
- Northwest Kinetics
-
-
-
-
-
Antigua Guatemala, Guatemala, 03001
- Private Clinic Antigua
-
-
-
-
Guanajuata
-
San Miguel de Allende, Guanajuata, Mexiko, 37700
- Private Clinic San Miguel
-
-
Jalisco
-
Guadalajara, Jalisco, Mexiko, 44690
- Private Clinic Guadalajara
-
-
Marina Vallarta
-
Puerto Vallarta, Marina Vallarta, Mexiko, 48334
- AmeriMed Hospital
-
-
Morelos
-
Cuernavaca, Morelos, Mexiko, 62250
- Private Clinic Cuernavaca
-
-
Quintana Roo
-
Cancun, Quintana Roo, Mexiko, 77500
- Hospital Americano
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Healthy adult men and women 18-64 years of age inclusive at screening
- Signed Informed Consent form
- Planned travel to an area within 2 ½ hours traveling distance of Cuernavaca or Guadalajara, Mexico or Antigua, Guatemala (minimum stay of 7 days)
- If female who is not post-menopausal or surgically sterile, negative pregnancy test (within 24 hours prior to vaccination) and agreement to employ an effective form of birth control or practice abstinence through the end of the study.
Exclusion Criteria:
- Clinically significant abnormalities as determined by the Investigator/clinician during physical inspection
- Received investigational product from 30 days before date of first vaccination or during the entire study period
- Ever received LT, ETEC, or cholera vaccine
- History of traveler's diarrhea within the previous year
- Travel to a developing country within the last year
- Women who are pregnant or breastfeeding
- History of achlorhydria
- Evidence of immunosuppression, including concomitant immunosuppressive therapy; fever > 99.5°F (37.5°C) on day of vaccination
- Current problems with alcohol or substance abuse
- An employee of the study clinic
- Sensitivity or allergy to any of the vaccine components
- History of significant blood loss, blood product donation, or blood product recipient in the previous 60 days
- Planned use of Imodium or antibiotics for self treatment of diarrhea during the study period
- Visible tattoos or marks (tattoos/scars) at the vaccination areas that would prevent appropriate dermatologic monitoring of the vaccination sites; and
- Medical history of acute or chronic GI illness or major GI surgery.
Studieplan
Hur är studien utformad?
Designdetaljer
- Tilldelning: Randomiserad
- Interventionsmodell: Faktoriell uppgift
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Group 1
Group 1 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 37.5µg LT
|
Subjects in Group 1 will receive two vaccinations of a patch containing 37.5µg LT 2 to 3 weeks apart.
|
Placebo-jämförare: Group 2
Group 2 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 0µg LT (placebo patch containing no LT)
|
The placebo patch contains all of the components of the active patch, but with no LT included in the formulation.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Incidence of Enterotoxigenic Escherichia coli (ETEC) illness defined as a diarrheal episode associated with an LT, LT/ST, or ST-positive ETEC strain isolated from a sample of a stool
Tidsram: during the diarrheal episode or within 48 hours after the last stool in the diarrheal episode.
|
during the diarrheal episode or within 48 hours after the last stool in the diarrheal episode.
|
Safety of heat-labile enterotoxin of Escherichia coli (LT) delivered by transcutaneous immunization (TCI) vs placebo
Tidsram: From vaccination 1 to completion of Day 180 follow-up, about a seven month time period
|
From vaccination 1 to completion of Day 180 follow-up, about a seven month time period
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Stool frequency per episode of ETEC illness in placebo recipients
Tidsram: Duration of stay in Mexico or Guatemala assessed up to four weeks
|
Duration of stay in Mexico or Guatemala assessed up to four weeks
|
Immunogenicity of LT delivered by TCI
Tidsram: at least three weeks prior to arrival in country, arrival in Mexico or Guatemala, and 5 to 18 days after arrival
|
at least three weeks prior to arrival in country, arrival in Mexico or Guatemala, and 5 to 18 days after arrival
|
Incidence of irritable bowel syndrome following travel to areas of ETEC endemnicity.
Tidsram: Baseline through six months post return from Latin America. A period of about six months.
|
Baseline through six months post return from Latin America. A period of about six months.
|
Incidence of vaccine preventable outcome in placebo and LT patch recipients.
Tidsram: Duration of each individual participant stay in Mexico or Guatemala ranging from 7 to 28 Days.
|
Duration of each individual participant stay in Mexico or Guatemala ranging from 7 to 28 Days.
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Herbert L. DuPont, MD, Center for Infectious Diseases, The University of Texas Health Science Center at Houston
- Huvudutredare: Robin McKenzie, MD, Johns Hopkins University, Bloomberg School of Public Health
- Huvudutredare: Rama Yerramsetti, Breco Research, Houston, TX
- Huvudutredare: William P Jennings, Radiant Research, San Antonio, TX
- Huvudutredare: Yu-Luen Hsu, West Coast Clinical Trials, Long Beach, CA
- Huvudutredare: Christopher A Smith, Asthma & Allergy Associates, Ithaca, NY
- Huvudutredare: Benno G Roesch, Advanced Biomedical Research, Hackensack, NJ
- Huvudutredare: Jeffrey G Geohas, Radiant Research, Chicago, IL
- Huvudutredare: Gilbert Podolsky, Jean Brown Research, Salt Lake City, UT
- Huvudutredare: Thomas Lagen, Northwest Kinetics, Tacoma, WA
- Huvudutredare: Roy M Fleischmann, Radiant Research, Dallas, TX
- Huvudutredare: Douglas R Schumacher, Radiant Research, Columbus, OH
- Huvudutredare: Norman M Lunde, Twin Cities Clinical Research, Minneapolis, MN
- Huvudutredare: Francisco G Sandoval, Universidad Autonoma De Guadalajara, Mexico
- Huvudutredare: Juan Hector M Romero, Universidad Autonoma Guadalajara, Mexico
- Huvudutredare: Jaime B Gerson, University of Texas, Cuernavaca, Mexico
- Huvudutredare: Edwin Asturias, Universidad del Valle de Guatemala (Antigua)
- Huvudutredare: Roberto Garcia, AmeriMed Puerto Vallarta, Mexico
- Huvudutredare: Martha V Serrato, Hospital Americano, Cancun, Mexico
- Huvudutredare: Robert Maxwell, Private Clinic, San Miguel de Allende, Mexico
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- ELT206
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Heat-Labile Enterotoxin of Escherichia coli (LT)
-
Intercell USA, Inc.Avslutad
-
Intercell USA, Inc.AvslutadResenärsdiarréFörenta staterna
-
Intercell USA, Inc.Avslutad
-
Intercell USA, Inc.Avslutad